Tested Applications
| Positive WB detected in | HepG2 cells, Jurkat cells, Raji cells |
| Positive IHC detected in | human tonsillitis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
19055-1-AP targets Aiolos/IKZF3 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag5537 Product name: Recombinant human IKZF3 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 209-509 aa of BC032707 Sequence: RSYKQRSSLEEHKERCRTFLQSTDPGDTASAEARHIKAEMGSERALVLDRLASNVAKRKSSMPQKFIGEKRHCFDVNYNSSYMYEKESELIQTRMMDQAINNAISYLGAEALRPLVQTPPAPTSEMVPVISSMYPIALTRAEMSNGAPQELEKKSIHLPEKSVPSERGLSPNNSGHDSTDTDSNHEERQNHIYQQNHMVLSRARNGMPLLKEVPRSYELLKPPPICPRDSVKVINKEGEVMDVYRCDHCRVLFLDYVMFTIHMGCHGFRDPFECNMCGYRSHDRYEFSSHIARGEHRALLK Predict reactive species |
| Full Name | IKAROS family zinc finger 3 (Aiolos) |
| Calculated Molecular Weight | 509 aa, 58 kDa |
| Observed Molecular Weight | 58-70 kDa |
| GenBank Accession Number | BC032707 |
| Gene Symbol | IKZF3 |
| Gene ID (NCBI) | 22806 |
| RRID | AB_10643381 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9UKT9 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
IKZF3, also named as Zinc finger protein Aiolos or ZNFN1A3, is a 509 amino acid protein, which contains 6 C2H2-type zinc fingers and belongs to the Ikaros C2H2-type zinc-finger protein family. IKZF3 localizes in the nucleus and cytoplasm. IKZF3 can form homodimer, and heterodimer with other IKAROS family members. IKZF3 is expressed most strongly in peripheral blood leukocytes, the spleen, and the thymus. IKZF3 as a transcription factor plays an important role in the regulation of lymphocyte differentiation. The calculated molecular weight of IKZF3 is 58 kDa, but the modified IKZF3 protein is about 65-70 kDa.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for Aiolos/IKZF3 antibody 19055-1-AP | Download protocol |
| IHC protocol for Aiolos/IKZF3 antibody 19055-1-AP | Download protocol |
| WB protocol for Aiolos/IKZF3 antibody 19055-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Anti-IKZF3 (Aiolos), catalog number 19055-1-AP, has 10 total citations. These appear in journals including Cancer Research, Cell Death Discovery, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Scientific Reports, Journal of Clinical Immunology, and Journal of Gastroenterology and Hepatology. Associated research fields span anticancer drug discovery (PROTAC degraders targeting SOS1, BTK, IRAK4, PARP1, and FLT3), leukemia, gastric cancer progression, epithelial-mesenchymal transition, and combined immunodeficiency.
| Species | Application | Title |
|---|---|---|
Cancer Res Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia | ||
Cell Death Discov IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform. | ||
J Med Chem Identification of XZ8078 as a Dual-Target Degrader Targeting PARP1 and IKZF3 for Broad Spectrum Anticancer Treatment. | ||
J Med Chem Discovery of the First-in-Class Protein Arginine Methyltransferase 1 PROTAC Degrader. | ||
J Med Chem Discovery of Rigid Linker-Based IRAK4 PROTACs with Improved Metabolic Stability for the Treatment of Inflammatory Diseases. | ||
Eur J Med Chem Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy |
